Research Programme: anti-cancer therapeutics - Rafael Pharmaceuticals/National Cancer Institute

Drug Profile

Research Programme: anti-cancer therapeutics - Rafael Pharmaceuticals/National Cancer Institute

Alternative Names: Emulsiphan anti-cancer therapeutics

Latest Information Update: 07 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cornerstone Pharmaceuticals; National Cancer Institute (USA)
  • Developer National Cancer Institute (USA); Rafael Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 05 Jun 2017 Cornerstone Pharmaceuticals is now called Rafael Pharmaceuticals
  • 23 Mar 2010 Preclinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top